The workplace is gradually becoming a hotspot in the battle against the opioid crisis. With the rise of opioid overdoses in the United States – from 21,089 in 2010 to more than 80,000 in 2021 and 2022 – employers are considering innovative measures to protect their workforce. The U.S. Centers for Disease Control and Prevention (CDC) has been a valuable resource in providing data on this alarming trend.
One approach garnering significant attention is the stocking of Naloxone in workplaces. Naloxone, also known by its brand names Narcan and Evzio, is an opioid antagonist used for the emergency treatment of a known or suspected opioid overdose. The drug, when administered in a timely manner, can drastically increase the survival chances of an individual experiencing an opioid overdose.
However, its introduction into the workplace is not without pitfalls. Employers must be cautious of potential legal ramifications, from the issues of administration and training to storage and access. Additionally, the question of liability in case of improper administration or unforeseen adverse reactions remains a point of concern.
While it is clear that the wellbeing of employees is paramount, an employer’s decision to stock Naloxone should be grounded in a comprehensive assessment of legal and practical implications. A thorough understanding of related health and safety laws, as well as consultation with legal counsellors and healthcare providers is advised.
For detailed insight, please refer to the article Stocking Naloxone in the Workplace: What Employers Need to Consider published by Ogletree, Deakins, Nash, Smoak & Stewart.